Blood Reviews

Papers
(The TQCC of Blood Reviews is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond117
Pitfalls in laboratory monitoring of treatment in people with Haemophilia116
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders115
Editorial Board107
Not all LGL leukemias are created equal78
Transplant-acquired allergy in HCT-recipients: Reference for clinical management66
Clinical burden of hemophilia in older adults: Beyond bleeding risk58
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?56
Artificial intelligence in sickle disease53
Radiation and leukaemia: Which leukaemias and what doses?53
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload51
Thalassaemia in China47
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach45
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond40
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia38
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma38
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia38
Chasing leukemia differentiation through induction therapy, relapse and transplantation37
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT37
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies36
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]36
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs36
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk34
CHIPing away the progression potential of CHIP: A new reality in the making33
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification33
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need33
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis32
Preservation of fertility in female patients with hematologic diseases31
Harnessing multi-source data for individualized care in Hodgkin Lymphoma31
Endothelial cells: major players in acute myeloid leukaemia31
Immune thrombocytopenia: A review of upfront treatment strategies31
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?30
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature29
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions29
Down syndrome and leukemia: An insight into the disease biology and current treatment options28
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria28
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines28
Current challenges in conditioning regimens for MDS transplantation28
Richter's transformation: Transforming the clinical landscape26
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis26
The extracellular matrix: A key player in the pathogenesis of hematologic malignancies25
Optimizing high dose melphalan25
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation25
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma25
The mythological chimera and new era of relapse prediction post-transplant25
Current state and next-generation CAR-T cells in multiple myeloma24
Complementary and alternative medicine for children with sickle cell disease: A systematic review23
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?22
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia22
Αlpha-thalassemia: A practical overview21
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease21
AML and the art of remission maintenance20
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned20
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape20
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion19
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?19
Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement19
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis19
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy19
Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies19
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy18
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers18
The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies17
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML17
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data17
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency17
Innovations in red blood cell preservation17
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines17
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment17
Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies17
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?16
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia16
Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy16
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence16
A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease16
0.098458051681519